T. Rowe Price Associates
RDUS

T. Rowe Price Associates’s Radius Health, Inc. RDUS Stock Holding History

T. Rowe Price Associates’s Portfolio RDUS Stock Details RDUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,631,498
Closed -$14.4M – 3029
2022
Q1 		$14.4M Buy
1,631,498
+37,451
+2% +$284K ﹤0.01% 1311
2021
Q4 		$11M Sell
1,594,047
-6,097,624
-79% -$89.5M ﹤0.01% 1396
2021
Q3 		$95.5M Sell
7,691,671
-278,505
-3% -$4.01M 0.01% 785
2021
Q2 		$145M Buy
7,970,176
+15,891
+0.2% +$316K 0.01% 658
2021
Q1 		$166M Buy
7,954,285
+1,604,837
+25% +$33.8M 0.02% 607
2020
Q4 		$113M Buy
6,349,448
+1,492,437
+31% +$22.4M 0.01% 690
2020
Q3 		$55.1M Sell
4,857,011
-603,502
-11% -$7.46M 0.01% 832
2020
Q2 		$74.4M Sell
5,460,513
-45,120
-0.8% -$621K 0.01% 718
2020
Q1 		$71.6M Sell
5,505,633
-334,661
-6% -$5.97M 0.01% 672
2019
Q4 		$118M Buy
5,840,294
+1,240,621
+27% +$30.1M 0.02% 614
2019
Q3 		$118M Buy
4,599,673
+724,360
+19% +$17.8M 0.02% 579
2019
Q2 		$94.4M Buy
3,875,313
+1,314,899
+51% +$28.7M 0.01% 663
2019
Q1 		$51.1M Buy
2,560,414
+22,283
+0.9% +$406K 0.01% 872
2018
Q4 		$41.9M Buy
2,538,131
+19,958
+0.8% +$336K 0.01% 887
2018
Q3 		$44.8M Sell
2,518,173
-1,634,754
-39% -$37M 0.01% 954
2018
Q2 		$122M Sell
4,152,927
-940,350
-18% -$29.7M 0.02% 607
2018
Q1 		$183M Sell
5,093,277
-1,161,919
-19% -$42M 0.03% 485
2017
Q4 		$199M Sell
6,255,196
-872,637
-12% -$27.4M 0.03% 464
2017
Q3 		$275M Buy
7,127,833
+76,975
+1% +$3.02M 0.05% 381
2017
Q2 		$319M Buy
7,050,858
+3,079,397
+78% +$118M 0.06% 333
2017
Q1 		$153M Buy
3,971,461
+891,630
+29% +$37.4M 0.03% 491
2016
Q4 		$117M Buy
3,079,831
+2,027,813
+193% +$96.5M 0.02% 553
2016
Q3 		$56.9M Buy
1,052,018
+463,447
+79% +$23.6M 0.01% 767
2016
Q2 		$21.6M Buy
588,571
+574,011
+3,942% +$20.3M ﹤0.01% 1075
2016
Q1 		$458K Buy
14,560
+7,512
+107% +$260K ﹤0.01% 2013
2015
Q4 		$434K Buy
+7,048
New +$445K ﹤0.01% 2018

Other funds holding RDUS

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RP
Repertoire Partners New York $143M AUM 28.83% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

T. Rowe Price Associates's RDUS Position: Q2 2022 in Review

T. Rowe Price Associates sold out of Radius Health, Inc. (RDUS) in Q2 2022, closing a stake of 1,631,498 shares — an estimated $14.4M sold.

T. Rowe Price Associates first reported a position in RDUS in Q4 2015 and held it in 26 quarters. The position peaked at $319M in Q2 2017. 123 funds tracked by Wall St. Rank hold RDUS as of Q2 2022.

  • T. Rowe Price Associates reported no remaining Radius Health, Inc. position as of Q2 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,631,498 Radius Health, Inc. shares in Q2 2022, an estimated $14.4M.
  • T. Rowe Price Associates first reported a position in Radius Health, Inc. in Q4 2015 and held it in 26 quarters.
  • T. Rowe Price Associates's Radius Health, Inc. position peaked at $319M in Q2 2017.
  • 123 funds tracked by Wall St. Rank held Radius Health, Inc. as of Q2 2022.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.